RecruitingNCT05191381
Immune Modulation by Exosomes in COVID-19
Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19
Sponsor
University of Ulm
Enrollment
40 participants
Start Date
Dec 22, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria4
- Critically ill COVID-19 patients with lung dysfunction
- COVID-19 WHO severity degree >= 4, ARDS (WHO Definition 13 March 2020)
- Body weight > 50 kg
- Informed consent
Exclusion Criteria1
- Pregnant or breast feeding women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALApplication of exosomes in a whole blood assay
Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05191381
Related Trials
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
NCT072211628 locations
Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage
NCT040435983 locations
International Survey of Acute Coronavirus Syndromes-COVID-19
NCT051886122 locations
Impact of the Coronavirus (COVID-19) on Patients With Cancer
NCT043305211 location
Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
NCT071738556 locations